Small-cell cancer of the breast: what is the optimal treatment? A report and review of outcomes.

Autor: Ochoa R, Sudhindra A, Garcia-Buitrago M, Romilly AP, Cortes J, Gomez H, Rocha Lima CM, Silva O

Publikováno v: Clinical Breast Cancer; 2012 Aug, Vol. 12 Issue 4, p287-292, 6p

Bortezomib with or without irinotecan in relapsed or refractory colorectal cancer: results from a randomized phase II study.

Autor: Kozuch PS, Rocha-Lima CM, Dragovich T, Hochster H, O'Neil BH, Atiq OT, Pipas JM, Ryan DP, Lenz HJ, Kozuch, Peter S, Rocha-Lima, Caio Max, Dragovich, Tomislav, Hochster, Howard, O'Neil, Bert H, Atiq, Omar T, Pipas, J Marc, Ryan, David P, Lenz, Heinz-Josef

Publikováno v: Journal of Clinical Oncology; 5/2/2008, Vol. 26 Issue 14, p2320-2326, 7p

Trilaciclib dose selection: an integrated pharmacokinetic and pharmacodynamic analysis of preclinical data and Phase Ib/IIa studies in patients with extensive-stage small cell lung cancer.

Autor: Li C; G1 Therapeutics, Inc., Research Triangle Park, NC, USA.; Fosun Pharma USA, Inc., Lexington, MA, USA., Hart L; Florida Cancer Specialists, SCRI, Fort Myers, FL, USA.; Wake Forest Baptist Medical Center, Winston-Salem, NC, USA., Owonikoko TK; Winship Cancer Institute, Emory University, Atlanta, GA, USA., Aljumaily R; Stephenson Cancer Center and SCRI, University of Oklahoma, Oklahoma City, OK, USA., Rocha Lima CM; Wake Forest Baptist Medical Center, Winston-Salem, NC, USA., Conkling PR; US Oncology Research, Virginia Oncology Associates, Norfolk, VA, USA., Webb RT; Genesis Cancer Center, Hot Springs, AR, USA., Jotte RM; Rocky Mountain Cancer Centers, Denver, CO, USA., Schuster S; Poudre Valley Health System, Fort Collins, CO, USA., Edenfield WJ; Prisma Health Cancer Institute, Greenville, SC, USA., Smith DA; Nuventra Pharma Sciences, Durham, NC, USA., Sale M; Nuventra Pharma Sciences, Durham, NC, USA., Roberts PJ; G1 Therapeutics, Inc., Research Triangle Park, NC, USA.; Arc Therapeutics, Research Triangle Park, NC, USA., Malik RK; G1 Therapeutics, Inc., Research Triangle Park, NC, USA. rmalik@g1therapeutics.com., Sorrentino JA; G1 Therapeutics, Inc., Research Triangle Park, NC, USA.

Publikováno v: Cancer chemotherapy and pharmacology [Cancer Chemother Pharmacol] 2021 May; Vol. 87 (5), pp. 689-700. Date of Electronic Publication: 2021 Feb 17.

Myelopreservation with the CDK4/6 inhibitor trilaciclib in patients with small-cell lung cancer receiving first-line chemotherapy: a phase Ib/randomized phase II trial.

Autor: Weiss JM; Division of Hematology and Oncology, Lineberger Comprehensive Cancer Center at the University of North Carolina, Chapel Hill, USA., Csoszi T; Oncology, Hetenyi Geza Korhaz, Onkologiai Kozpont, Szolnok, Hungary., Maglakelidze M; Department of Oncology, Research Institute of Clinical Medicine, Tbilisi, Georgia, USA., Hoyer RJ; Department of Oncology, Memorial Hospital, University of Colorado Health, Colorado Springs, USA., Beck JT; Department of Medical Oncology and Hematology, Highlands Oncology Group, Fayetteville, USA., Domine Gomez M; Department of Oncology, University Hospital Fundacion Jimenez Diaz, IIS-FJD, Madrid, Spain., Lowczak A; Department of Pulmonology, Faculty of Health and Science, University of Warmia and Mazury in Olsztyn, Poland., Aljumaily R; Stephenson Cancer Center, University of Oklahoma, Oklahoma City, USA., Rocha Lima CM; Gibbs Cancer Center and Research Institute, Spartanburg, USA., Boccia RV; Center for Cancer and Blood Disorders, Bethesda, USA., Hanna W; Hematology/Oncology, University of Tennessee Medical Center, Knoxville, USA., Nikolinakos P; University Cancer & Blood Center, LLC, Athens, Greece., Chiu VK; Department of Hematology/Oncology, University of New Mexico Comprehensive Cancer Center, Albuquerque, USA., Owonikoko TK; Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, USA., Schuster SR; University of Colorado, Fort Collins, USA., Hussein MA; Department of Oncology, Florida Cancer Specialists, Leesburg, USA., Richards DA; Department of Oncology, US Oncology Research, Tyler, USA., Sawrycki P; Department of Cancer Chemotherapy, Provincial Hospital, Toruń, Poland., Bulat I; ARENSIA Oncology Unit, Institute of Oncology, Chisinau, Moldova., Hamm JT; Department of Medical Oncology, Norton Health Care, Louisville, USA., Hart LL; Drug Development Program, Floridia Cancer Specialists, Fort Myers, USA., Adler S; Clinical Research, G1 Therapeutics, Inc., Research Triangle Park, USA., Antal JM; Clinical Research, G1 Therapeutics, Inc., Research Triangle Park, USA., Lai AY; Clinical Research, G1 Therapeutics, Inc., Research Triangle Park, USA., Sorrentino JA; Clinical Research, G1 Therapeutics, Inc., Research Triangle Park, USA., Yang Z; Clinical Research, G1 Therapeutics, Inc., Research Triangle Park, USA., Malik RK; Clinical Research, G1 Therapeutics, Inc., Research Triangle Park, USA., Morris SR; Clinical Research, G1 Therapeutics, Inc., Research Triangle Park, USA., Roberts PJ; Clinical Research, G1 Therapeutics, Inc., Research Triangle Park, USA., Dragnev KH; Department of Hematology/Oncology, Norris Cotton Cancer Center Dartmouth-Hitchcock Medical Center, Lebanon, USA. Electronic address: konstantin.h.dragnev@hitchcock.org.

Publikováno v: Annals of oncology : official journal of the European Society for Medical Oncology [Ann Oncol] 2019 Oct 01; Vol. 30 (10), pp. 1613-1621.

The nab -paclitaxel/gemcitabine regimen for patients with refractory advanced pancreatic adenocarcinoma.

Autor: Palacio S; Department of Medicine, University of Miami Miller School of Medicine and Sylvester Comprehensive Cancer Center, Miami, FL, USA., Hosein PJ; Department of Medicine, University of Miami Miller School of Medicine and Sylvester Comprehensive Cancer Center, Miami, FL, USA., Reis I; Department of Medicine, University of Miami Miller School of Medicine and Sylvester Comprehensive Cancer Center, Miami, FL, USA., Akunyili II; Department of Medicine, University of Miami Miller School of Medicine and Sylvester Comprehensive Cancer Center, Miami, FL, USA., Ernani V; Department of Medicine, University of Nebraska Medical Center, Omaha, NE, USA., Pollack T; Department of Medicine, University of Miami Miller School of Medicine and Sylvester Comprehensive Cancer Center, Miami, FL, USA., Macintyre J; Department of Medicine, University of Miami Miller School of Medicine and Sylvester Comprehensive Cancer Center, Miami, FL, USA., Restrepo MH; Department of Medicine, University of Miami Miller School of Medicine and Sylvester Comprehensive Cancer Center, Miami, FL, USA., Merchan JR; Department of Medicine, University of Miami Miller School of Medicine and Sylvester Comprehensive Cancer Center, Miami, FL, USA., Rocha Lima CM; Division of Oncology, Gibbs Comprehensive Cancer Center and Research Institute, Spartanburg, SC, USA.

Publikováno v: Journal of gastrointestinal oncology [J Gastrointest Oncol] 2018 Feb; Vol. 9 (1), pp. 135-139.